Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...

The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) underscores the urgent need for innovative ...

After reviewing all the data and considering input from regulators, Pfizer decided to discontinue the danuglipron program.

In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval ...

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to ...

Pfizer (PFE) announced the decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Among U.S. adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to ...

Morbidly obese patients remain an unsolved clinical problem,” explained co-author Gwo-Chin Lee, M.D., a hip and knee replacement surgeon at HSS. “Traditional weight loss measures have had mixed ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

In the long term, bariatric surgery is more cost-effective than new anti-obesity medications, research finds, triggering a ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...